Quizartinib

Known as: (2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide, AC220 compound, N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea 
An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1983-2018
051019832018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
FLT3-ITD-mutated acute myeloid leukemia (AML) has very high risk of relapse and is associated with poor outcome following… (More)
Is this relevant?
2015
2015
UNLABELLED Tyrosine kinase domain mutations are a common cause of acquired clinical resistance to tyrosine kinase inhibitors (TKI… (More)
Is this relevant?
2015
2015
More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) are… (More)
Is this relevant?
2013
2013
Fms-like tyrosine kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML). FLT3-activating internal… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2013
2013
The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Effective targeted cancer therapeutic development depends upon distinguishing disease-associated ‘driver’ mutations, which have… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2012
2012
A hallmark of cancer is the disruption of differentiation within tumor cells. Internal tandem duplication mutations of the FLT3… (More)
  • table 1
  • table 2
Is this relevant?